<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881933</url>
  </required_header>
  <id_info>
    <org_study_id>KSPHO-SCT0804</org_study_id>
    <nct_id>NCT00881933</nct_id>
  </id_info>
  <brief_title>Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)</brief_title>
  <official_title>Phase I/II Study of Fludarabine, Cyclophosphamide Plus TBI Conditioning Regimen for Double Units Cord Blood Transplantation in Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Korean Society of Pediatric Hematology Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Korean Society of Pediatric Hematology Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe aplastic anemia is a fatal disease and patients without HLA matched siblings need
      alternative treatment option. Cord blood transplantation (CBT) has become an alternative
      treatment means in various diseases, but it has not been proved to be good for severe
      aplastic anemia. Double units CBT is proposed to have better engraftment potential and and we
      reported successful double units UCBT after engraftment failure with single unit with
      promising result. To increase the engraftment potential, fludarabine, cyclophosphamide plus
      TBI conditioning regimen for double units cord blood transplantation was proposed for the
      patient with severe aplastic anemia without HLA-matched donor.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the engraftment potential of fludarabine, busulfan plus thymoglobulin conditioning regimen for cord blood transplantation (CBT) in severe aplastic anemia.</measure>
    <time_frame>From Oct 2008. to Sep 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence and severity of toxicity and treatment related mortality</measure>
    <time_frame>From Oct 2008. to Sep 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate overall and event free survival rate</measure>
    <time_frame>From Oct 2008. to Sep 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate acute and chronic GVHD</measure>
    <time_frame>From Oct 2008. to Sep 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunologic recovery after CBT</measure>
    <time_frame>From Oct 2008. to Sep 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cyclophosphosphamide, TBI</intervention_name>
    <description>fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, &amp; -2) (if body weight &lt; 10 kg or if age &lt; 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, &amp; -8) total body irradiation (3G on days -1)</description>
    <arm_group_label>Fludarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe aplastic anemia defined by any two or three peripheral blood
             criteria and either marrow criterion.

          -  Peripheral blood

               -  Neutrophils &lt; 0.5 x 109/l

               -  Platelets &lt; 20 x 109/l

               -  Corrected reticulocytes &lt; 1%

          -  Bone marrow

               -  Severe hypocellularity (&lt; 25%)

               -  Moderate hypocellularity (25-30%) with hematopoietic cells representing &lt; 30% of
                  residual cells

          -  No prior hematopoietic stem cell transplantation.

          -  Age: no limits.

          -  Performance status: ECOG 0-2.

          -  Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases.

               -  Heart: a shortening fraction &gt; 30%, ejection fraction &gt; 45%.

               -  Liver: total bilirubin &lt; 2 × upper limit of normal; ALT &lt; 3 × upper limit of
                  normal.

               -  Kidney: creatinine &lt;2 × normal or a creatinine clearance (GFR) &gt; 60
                  ml/min/1.73m2.

          -  Patients must lack any active viral infections or active fungal infection.

          -  No appropriate donor

          -  Appropriate cord blood is available: matched at least in 4/6 of A, B, DR loci.

          -  Patients (or one of parents if patients age &lt; 19) should sign informed consent.

        Exclusion Criteria:

          -  Pregnant or nursing women.

          -  Malignant or nonmalignant illness that is uncontrolled or whose control may be
             jeopardized by complications of study therapy.

          -  Psychiatric disorder that would preclude compliance.

          -  Congenital aplastic anemia including Fanconi anemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo Seop Ahn, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Korean Society of Pediatric Hematology Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
    <phone>82 2 2072 3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Won Lee, M.D</last_name>
    <phone>82 2 2072 0177</phone>
    <email>agnesjw@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Seop Ahn, M.D, Ph.D</last_name>
      <phone>82 2 2072 3625</phone>
      <email>hsahn@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>The Korean Society of Hematology</name_title>
    <organization>The Korean Society of Pediatric Hematology Oncology</organization>
  </responsible_party>
  <keyword>Fludarabine, Cyclophosphamide, TBI, severe aplastic anemia,</keyword>
  <keyword>cord blood transplantation, pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

